Insmed Incorporated (INSM)
Healthcare · NMS
Price as at 1 Oct 2026, 22:21 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Insmed Incorporated trades at $108.59, which is 60% above the $43.45 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 48 out of 100, which is a moat, but not a deep one. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
INSM earnings and analyst estimates
Recommendation mix, 22 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Insmed Incorporated
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
INSM passes 2 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
13 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- D. E. Shaw, D. E. Shaw & Co., Inc.$626.71M · 0.3% of book
- Ken Griffin, CITADEL ADVISORS LLC$272.62M · 0.0% of book
- Lee Ainslie, MAVERICK CAPITAL LTD$229.31M · 2.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$218.36M · 0.1% of book
- Stanley Druckenmiller, Duquesne Family Office LLC$151.90M · 2.9% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in INSM
We hold 6 disclosed trades in INSM by members of Congress and executive-branch officials. The latest 5:
- Josh Gottheimer · HouseSell · $1,001 - $15,000 · traded 10 Jun 2026 · disclosed 7 Jul 2026
- Donald J Trump · Executive branchSell · $1,001 - $15,000 · traded 28 Apr 2026 · disclosed 1 Jul 2026
- Gilbert Cisneros · HouseSell · $1,001 - $15,000 · traded 3 Oct 2025 · disclosed 18 Nov 2025
- Gilbert Cisneros · HouseSell · $1,001 - $15,000 · traded 22 Sept 2025 · disclosed 10 Oct 2025
- Gilbert Cisneros · HouseSell · $1,001 - $15,000 · traded 8 Aug 2025 · disclosed 12 Sept 2025
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
INSM peers
The largest companies in the same industry (Biotechnology), then in the same sector.
- CSLLY CSL Limited
- RVMD Revolution Medicines, Inc.
- CMXHF CSL Limited
- ALNY Alnylam Pharmaceuticals, Inc.
- RPRX Royalty Pharma plc
- INCY Incyte Corporation
- GNMSF Genmab A/S
- JAZZ Jazz Pharmaceuticals plc
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is Insmed Incorporated (INSM) undervalued?
Against our fair value estimate of $43.45, INSM at $108.59 is 60% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own INSM?
13 of the institutions we track reported a position in INSM in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its INSM data?
Fundamentals for INSM come from company filings and exchange data, as listed on NMS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 22:21 UTC and is delayed. Our data quality score for this company is 83/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for INSM, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.